KaydedilenlerDerginizi ekleyin

Dergiler / Haydarpaşa Numune Medical Journal / 2018 / Cilt: 58 - Sayı: 1

Rifaximin-induced Neutropenia in Patients with Cirrhosis

Ayça SALTÜRK
Can GÖNEN
Osman BEDİR
Sayfa
56–57
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Rifaximin is an antibiotic of the rifamycin family.
📊
Temel Bulgular & Veri:In patients with liver damage, however, the systemic effect increases as the severity of liver damage increases.
💡
Sonuç & Katkı:This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Rifaximin is an antibiotic of the rifamycin family. In healthy individuals, it is very poorly absorbed into the blood stream. In patients with liver damage, however, the systemic effect increases as the severity of liver damage increases. This case is presented to highlight the fact that neutropenia can develop due to rifaximin use in patients with hepatic cirrhosis.

🔖

Bu Makaleye Atıf Yap

SALTÜRK, A., GÖNEN, C., BEDİR, O. (2018). Rifaximin-induced Neutropenia in Patients with Cirrhosis. Haydarpaşa Numune Medical Journal, Cilt: 58 - Sayı: 1, 56–57. https://ajindex.com/articles/215297

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL. Available at: https:// www.aasld.org/sites/default/files/guideline_documents/hepaticencephenhanced. pdf. Accessed Feb 16, 2018
  2. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473–9. [CrossRef ] 3. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs 2005;65:1697–713
  3. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071–81. [CrossRef ] 5. Chitre MM, Berenson CS. Idiosyncratic rifabutin-induced leukopenia and SIADH: case report and review. Pharmacotherapy 2001;21:493–7. [CrossRef ] 6. van Assendelft AH. Leucopenia caused by two rifampicin preparations. Eur J Respir Dis 1984;65:251–8
  4. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51–6
  5. Xifaxan (rifaximin) product information. Morrisville, NC: Salix Pharmaceuticals; 2010 Nov. Available at: https://www.accessdata. fda.gov/drugsatfda_docs/appletter/2010/021361s009ltr. pdf. Accessed Feb 16, 2018
  6. Hynicka LM, Silva KN. Probable rifaximin-induced neutropenia. Am J Health Syst Pharm 2012;69:583–6. [CrossRef ]